---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-276826"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2021-09-20T23:59:59+00:00"
generated_at: "2026-06-29T02:35:42.087563+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience appoints Brendan Delaney as COO effective Sept 20, 2021

## Summary
- Delaney previously Chief Commercial Officer at Constellation Pharmaceuticals (acquired by MorphoSys for $1.4B) and Immunomedics.
- Annual base salary of $480,000, target bonus of 45%, and option to purchase 260,000 shares vesting over 4 years.
- Severance includes 12 months base salary plus COBRA reimbursement; full acceleration of equity upon change-in-control termination.
- Company highlights upcoming PDUFA date of Nov 26, 2021 for ABI-009 in PEComa and plans to initiate registrational trial for TSC1/TSC2 alterations.
- Delaney will establish Aadi's East Coast presence; has prior roles at Celgene/BMS and Novartis.

## SEC filing metadata
- accession: 0001193125-21-276826
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2021-09-20T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312521276826/0001193125-21-276826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312521276826/d234049d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-276826
- JSON: https://secwatch.observer/filing/0001193125-21-276826.json
- Plain text: https://secwatch.observer/filing/0001193125-21-276826.txt

## Key facts
- Executive change
  Brendan Delaney was appointed as Chief Operating Officer at Whitehawk Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On September 19, 2021, Aadi Bioscience, Inc. (the “ Company ”) appointed Brendan Delaney as the Company’s Chief Operating Officer, effective September 20, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312521276826/0001193125-21-276826-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.